newsfilter
← Latest News
ACCESS Newswire·

Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai

  • Ensysce Biosciences President James Morrison attended the Family Office Summit in Dubai on October 15, 2026, to engage with Middle East family offices.
  • The meetings focused on introducing Ensysce's severe chronic pain pipeline, specifically the CRPS candidate CY200, & initiating long-term investor relationships in the region.
  • CY200 is a key component of Ensysce's growth strategy following the August 2026 acquisition of Cy Biopharma.
  • In September 2026, Ensysce submitted the protocol for a Phase 2a clinical study of CY200 to the UK Medicines and Healthcare products Regulatory Agency.
  • CY200 has received Orphan Drug Designation from the FDA for treating Complex Regional Pain Syndrome (CRPS), a condition with no currently approved FDA therapies.
  • Ensysce develops neuroplastogenic therapies using psychedelics for chronic pain & a new class of novel opioids designed to minimize abuse & overdose risks.
  • The UAE is identified as a major international center for capital & healthcare innovation, aligning with Ensysce's goal of expanding its global investor community.